Rice Hall James & Associates, LLC Viridian Therapeutics, Inc.\De Transaction History
Rice Hall James & Associates, LLC
- $1.53 Billion
- Q1 2025
A detailed history of Rice Hall James & Associates, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 362,893 shares of VRDN stock, worth $4.92 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
362,893
Previous 53,375
579.89%
Holding current value
$4.92 Million
Previous $1.02 Million
378.1%
% of portfolio
0.32%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
203Shares Held
79.7MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$64.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$62.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$61.3 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$52.6 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$47.7 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $540M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...